Sagimet Biosciences Inc. 8-K

What Happened
Sagimet Biosciences Inc. announced on June 12, 2026 that Board member Tim Walbert resigned effective June 12, 2026, citing other commitments and stating the resignation was not due to any disagreement with the company. At the company’s virtual 2026 Annual Meeting of Stockholders on June 12, 2026 (record date April 17, 2026; 32,017,613 shares outstanding), shareholders elected four Class III directors—Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D.—each to serve until the 2029 annual meeting. The shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Tim Walbert resigned from the Board effective June 12, 2026; resignation attributed to other commitments and not to any disagreement with the company.
• Director election vote totals (For / Withheld / Broker Non-Votes):
  • Jennifer Jarrett: 6,461,429 / 2,555,268 / 10,124,106
  • Anne Phillips, M.D.: 7,806,504 / 1,210,193 / 10,124,106
  • David Happel: 8,753,884 / 262,813 / 10,124,106
  • George Kemble, Ph.D.: 8,688,684 / 328,013 / 10,124,106
• KPMG LLP ratified as independent auditor for 2026: For 19,091,619; Against 13,960; Abstentions 35,224; Broker Non-Votes 0.
• Record date for the meeting was April 17, 2026; 32,017,613 shares of Series A common stock were outstanding.

Why It Matters
Board membership and auditor appointments are important governance items for investors. The resignation of Mr. Walbert reduces the Board by one member but was described as non-contentious. The election results confirm the four named directors will serve through 2029, which affects board oversight and strategic continuity. Ratifying KPMG as the independent auditor sets the firm that will audit the company's 2026 financial statements, a routine but material governance vote for shareholders.